Your one point of contact for Actelion services and support
MEET A REP
To meet with an Actelion representative, click here
FORMS
For downloadable enrollment forms, click here
As a healthcare professional, you serve as a valuable resource for your patients on Tracleer or Ventavis Inhalation Solution.. And PAH Pathways is here to support you in that effort.
PAH Pathways is a comprehensive solution to PAH patient management. Our experienced team will help take the hassle out of paperwork and processes, allowing you to focus on the bigger job at hand—managing your patients.
Find out more about the range of support programs PAH Pathways offers including enrollment, reimbursement and financial assistance, and education and support throughout every step of your patient's journey.
Get Materials ยปTracleer is indicated for the treatment of pulmonary arterial hypertension (PAH) in patients with WHO Class II-IV symptoms, to improve exercise ability and decrease the rate of clinical worsening. Patients with WHO Class II symptoms showed reduction in the rate of clinical deterioration and a trend for improvement in walk distance. Physicians should consider whether these potential benefits are sufficient to offset the risk of liver injury in WHO Class II patients, which may preclude future use as their disease progresses.
Tracleer Important Safety Information
Because of the associated risks, Tracleer may be prescribed only through the Tracleer Access Program. Potential for serious liver injury (including, after prolonged treatment, rare cases of liver failure and unexplained hepatic cirrhosis in a setting of close monitoring) – Liver monitoring of all patients is essential prior to initiation of treatment and monthly thereafter. High potential for major birth defects – Pregnancy must be excluded and prevented through the use of reliable forms of birth control; monthly pregnancy tests should be obtained.
Contraindicated for use with cyclosporine A and glyburide.
Please see full Prescribing Information, including BOXED WARNING and Medication Guide.
Ventavis is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms.
Important safety information about Ventavis:
In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. Ventavis should not be initiated in patients with systolic blood pressure less than 85 mm Hg. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension.
Please see full Prescribing Information